Humankind Investments LLC
Long book
$175.1M
Q1 2026
Positions
20
Top-10 weight
81%
concentration
Last quarter
+16.2%
SPY +14.8%
Turnover
64%
of book per quarter
Strategy in plain words
auto-generated from filingsHumankind Investments LLC is a wealth-management firm allocating client money, specialised in technology (60% of the long book), running a $175.1M US long book across 20 positions.
The portfolio is extremely concentrated — the top 10 positions are almost the whole book. Turnover is high — positions rotate quickly, so individual names matter less than the process. Current anchor positions: INVESCO QQQ TRUST SERIES 1, SS SPDR S&P 500 ETF TRUST-US, MICROSOFT CORP, APPLE INC, ISHARES RUSSELL 2000 ETF.
Over the last 9 quarters its long book ran on average 0.3pp per quarter behind the S&P 500, beating the index in 5 of 9 quarters. Its holdings are mechanical (indexing / client flows), so position changes carry no stock-picking signal.
Implied long-book return vs S&P 500
methodology: positions priced quarterly, no shorts/options Fund long book S&P 500
Q1 2024
+3.5%
Q2 2024
+5.6%
Q3 2024
-1.9%
Q4 2024
-2.0%
Q1 2025
+7.6%
Q2 2025
+8.9%
Q3 2025
+3.7%
Q4 2025
-4.3%
Q1 2026
+16.2%
Sector allocation
Technology 74%
Healthcare 26%
Long book by quarter
What does Humankind Investments own?
Q1 2026 13F| Company | Sector | Shares | Value | % of book | Change |
|---|---|---|---|---|---|
| MSFT MICROSOFT CORP | Technology | 51.1K | $18.9M | 10.8% | +98.1% |
| AAPL APPLE INC | Technology | 56.8K | $14.4M | 8.2% | Held |
| CSCO CISCO SYSTEMS INC | Technology | 83.9K | $6.5M | 3.7% | Held |
| BMY BRISTOL-MYERS SQUIBB CO | Healthcare | 100.0K | $6.1M | 3.5% | New |
| PFE PFIZER INC | Healthcare | 211.0K | $5.9M | 3.4% | New |
| SNPS SYNOPSYS INC | Technology | 10.0K | $4.0M | 2.3% | New |
| APGE APOGEE THERAPEUTICS INC | Healthcare | 17.5K | $1.5M | 0.8% | New |
| EXEL EXELIXIS INC | Healthcare | 26.5K | $1.1M | 0.6% | New |
| BMRN BIOMARIN PHARMACEUTICAL INC | Healthcare | 19.8K | $1.1M | 0.6% | New |
13F filing history
| Period | Form | Filed | Entries | Reported value | Flags | Source |
|---|---|---|---|---|---|---|
| Q1 2026 | 13F-HR | May 15, 2026 | 20 | $175.1M | canonical | SEC ↗ |
| Q4 2025 | 13F-HR | Feb 17, 2026 | 18 | $222.9M | canonical | SEC ↗ |
| Q3 2025 | 13F-HR | Nov 14, 2025 | 153 | $436.8M | canonical | SEC ↗ |
| Q2 2025 | 13F-HR | Aug 14, 2025 | 147 | $410.3M | canonical | SEC ↗ |
| Q1 2025 | 13F-HR | May 14, 2025 | 149 | $385.2M | canonical | SEC ↗ |
| Q4 2024 | 13F-HR | Feb 14, 2025 | 152 | $395.0M | canonical | SEC ↗ |
| Q3 2024 | 13F-HR | Nov 14, 2024 | 141 | $277.0M | canonical | SEC ↗ |
| Q2 2024 | 13F-HR | Aug 12, 2024 | 140 | $376.8M | canonical | SEC ↗ |
| Q1 2024 | 13F-HR | May 8, 2024 | 139 | $378.0M | canonical | SEC ↗ |